{"id":8291,"date":"2026-07-25T07:45:55","date_gmt":"2026-07-25T04:45:55","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8291"},"modified":"2026-07-25T07:45:57","modified_gmt":"2026-07-25T04:45:57","slug":"gen6050x-exon-50-skipping-base-editing-drug-one-year-results","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/gen6050x-exon-50-skipping-base-editing-drug-one-year-results\/","title":{"rendered":"GEN6050X Ekzon 50 Atlama Tedavisi: Bir Y\u0131ll\u0131k Sonu\u00e7lar Duchenne Kas Distrofisi \u0130\u00e7in Umut Verici Geli\u015fmeler G\u00f6steriyor"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>GenAssist Therapeutics taraf\u0131ndan geli\u015ftirilen GEN6050X ekzon 50 atlama tedavisi, Duchenne kas distrofisi (DMD) i\u00e7in de\u011ferlendirilen ilk baz d\u00fczenleme terapilerinden biri olarak giderek artan bir ilgi g\u00f6r\u00fcyor.<\/strong> Dystrofin geninin k\u0131salt\u0131lm\u0131\u015f bir versiyonunu ileten geleneksel gen terapilerinin aksine, GEN6050X, ekzon 50'nin atlanmas\u0131 i\u00e7in DNA'y\u0131 hassas bir \u015fekilde d\u00fczenlemek \u00fczere tasarlanm\u0131\u015ft\u0131r; bu da okuma \u00e7er\u00e7evesini potansiyel olarak geri kazand\u0131rarak v\u00fccudun i\u015flevsel bir dystrofin formu \u00fcretmesini sa\u011flar. Bu deneysel tedavi hen\u00fcz klinik geli\u015ftirmenin erken a\u015famalar\u0131nda olsa da, yeni yay\u0131nlanan bir y\u0131ll\u0131k klinik veriler, baz\u0131 hastalar i\u00e7in anlaml\u0131 ve kal\u0131c\u0131 faydalar sa\u011flayabilece\u011fini g\u00f6stermektedir.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#what-is-the-gen-6050-x-exon-50-skipping-base-editing-drug\">GEN6050X Ekzon 50 Atlama Tedavisi Nedir?<\/a><\/li><li><a href=\"#one-year-clinical-results-of-gen-6050-x\">GEN6050X&#039;in Bir Y\u0131ll\u0131k Klinik Sonu\u00e7lar\u0131<\/a><ul><li><a href=\"#motor-function-outcomes\">Motor Fonksiyon Sonu\u00e7lar\u0131<\/a><\/li><li><a href=\"#cardiac-function-results\">Kalp Fonksiyonu Sonu\u00e7lar\u0131<\/a><\/li><li><a href=\"#pulmonary-function-results\">Akci\u011fer Fonksiyon Test Sonu\u00e7lar\u0131<\/a><\/li><\/ul><\/li><li><a href=\"#safety-profile-of-the-gen-6050-x-exon-50-skipping-base-editing-drug\">GEN6050X Ekzon 50 Atlama Tedavisinin G\u00fcvenlik Profili<\/a><\/li><li><a href=\"#limitations-of-the-current-clinical-study\">Mevcut Klinik \u00c7al\u0131\u015fman\u0131n S\u0131n\u0131rlamalar\u0131<\/a><\/li><li><a href=\"#future-outlook-for-gen-6050-x\">GEN6050X i\u00e7in Gelecek Beklentileri<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 id=\"what-is-the-gen-6050-x-exon-50-skipping-base-editing-drug\" class=\"wp-block-heading\">GEN6050X Ekzon 50 Atlama Tedavisi Nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>GEN6050X \u015fu anda \u00c7in&#039;deki Pekin Birlik T\u0131p Fak\u00fcltesi Hastanesi&#039;nde y\u00fcr\u00fct\u00fclen, ara\u015ft\u0131rmac\u0131 taraf\u0131ndan ba\u015flat\u0131lan bir klinik \u00e7al\u0131\u015fmada (NCT06392724) incelenmektedir.<\/strong> \u0130lk \u00e7al\u0131\u015fmaya, ya\u015flar\u0131 6,5 ile 10 aras\u0131nda de\u011fi\u015fen, Duchenne kas distrofisi olan ve y\u00fcr\u00fcyebilen \u00fc\u00e7 erkek \u00e7ocuk dahil edildi. Her kat\u0131l\u0131mc\u0131ya 5 \u00d7 10\u00b9\u00b3 vg\/kg dozunda tek bir intraven\u00f6z GEN6050X inf\u00fczyonu uyguland\u0131. Son takipte, \u00fc\u00e7 kat\u0131l\u0131mc\u0131n\u0131n da bir y\u0131ll\u0131k izleme s\u00fcrecini tamamlad\u0131\u011f\u0131, ikisinin ise tedaviden sonra 18 aya ula\u015ft\u0131\u011f\u0131 g\u00f6r\u00fcld\u00fc. Daha Fazla Bilgi Edinin: <a href=\"https:\/\/dmdwarrior.com\/tr\/mutations-amenable-to-exon-50-skipping\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne Kas Distrofisinde Ekzon 50 Atlama Tedavisine Uygun Mutasyonlar<\/a><\/p>\n\n\n\n<h2 id=\"one-year-clinical-results-of-gen-6050-x\" class=\"wp-block-heading\">GEN6050X&#039;in Bir Y\u0131ll\u0131k Klinik Sonu\u00e7lar\u0131<\/h2>\n\n\n\n<h3 id=\"motor-function-outcomes\" class=\"wp-block-heading\">Motor Fonksiyon Sonu\u00e7lar\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fman\u0131n en cesaret verici y\u00f6nlerinden biri, klinik bulgular\u0131n kal\u0131c\u0131l\u0131\u011f\u0131d\u0131r. Duchenne kas distrofisinde, motor fonksiyon genellikle zamanla azal\u0131r.<\/strong> Ancak bir y\u0131l sonra ara\u015ft\u0131rmac\u0131lar, North Star Ambulatory Assessment (NSAA) puanlar\u0131n\u0131n ve Performance of Upper Limb 2.0 (PUL 2.0) puanlar\u0131n\u0131n sabit kald\u0131\u011f\u0131n\u0131 veya m\u00fctevaz\u0131 iyile\u015fmeler g\u00f6sterdi\u011fini bildirdi. Kat\u0131l\u0131mc\u0131 say\u0131s\u0131 \u00e7ok az olsa da, DMD gibi ilerleyici bir hastal\u0131kta motor fonksiyonun uzun s\u00fcre korunmas\u0131 cesaret verici bir sonu\u00e7 olarak kabul ediliyor.<\/p>\n\n\n\n<h3 id=\"cardiac-function-results\" class=\"wp-block-heading\">Kalp Fonksiyonu Sonu\u00e7lar\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Bildirilen faydalar sadece iskelet kaslar\u0131yla s\u0131n\u0131rl\u0131 de\u011fildi. <strong>Ara\u015ft\u0131rmac\u0131lar ayr\u0131ca kalp fonksiyonlar\u0131nda olumlu e\u011filimler g\u00f6zlemlediler; bu \u00f6zellikle \u00f6nemlidir \u00e7\u00fcnk\u00fc kalp hastal\u0131\u011f\u0131 Duchenne kas distrofisinde komplikasyonlar\u0131n ba\u015fl\u0131ca nedenlerinden biridir.<\/strong> \u00c7al\u0131\u015fma, her hastan\u0131n ba\u015flang\u0131\u00e7 \u00f6l\u00e7\u00fcmlerine k\u0131yasla sol ventrik\u00fcl ejeksiyon fraksiyonunda (LVEF) ortalama %5,32&#039;lik bir mutlak iyile\u015fme oldu\u011funu ortaya koymu\u015ftur. Kalp fonksiyonundaki bu iyile\u015fmeler, daha b\u00fcy\u00fck klinik \u00e7al\u0131\u015fmalarda do\u011frulan\u0131rsa, uzun vadeli sa\u011fl\u0131\u011fa potansiyel olarak katk\u0131da bulunabilir.<\/p>\n\n\n\n<h3 id=\"pulmonary-function-results\" class=\"wp-block-heading\">Akci\u011fer Fonksiyon Test Sonu\u00e7lar\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tedaviden sonra akci\u011fer fonksiyonlar\u0131nda da iyile\u015fme g\u00f6r\u00fcld\u00fc. Ba\u015flang\u0131\u00e7 de\u011ferleriyle kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, hastalarda Zorlu Vital Kapasitede (FVC) ortalama y\u00fczde 11.72 ve Tepe Ekspiratuvar Ak\u0131\u015f\u0131nda (PEF) y\u00fczde 25.29 iyile\u015fme kaydedildi.<\/strong> Bu \u00f6l\u00e7\u00fcmler, Duchenne kas distrofisi ilerledik\u00e7e kademeli olarak azalan akci\u011fer g\u00fcc\u00fcn\u00fc ve solunum kapasitesini de\u011ferlendirir. Ara\u015ft\u0131rmac\u0131lar, bu bulgular\u0131n GEN6050X&#039;in iskelet kas\u0131n\u0131n \u00f6tesine uzanan faydalar sa\u011flayabilece\u011fini g\u00f6sterdi\u011fini \u00f6ne s\u00fcrd\u00fcler, ancak bu erken g\u00f6zlemleri do\u011frulamak i\u00e7in daha b\u00fcy\u00fck \u00e7al\u0131\u015fmalara ihtiya\u00e7 duyulmaktad\u0131r.<\/p>\n\n\n\n<h2 id=\"safety-profile-of-the-gen-6050-x-exon-50-skipping-base-editing-drug\" class=\"wp-block-heading\">GEN6050X Ekzon 50 Atlama Tedavisinin G\u00fcvenlik Profili<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Deneysel genetik tedavilerde g\u00fcvenlik, en \u00f6nemli konulardan biri olmaya devam etmektedir. <strong>Bir y\u0131ll\u0131k takip sonu\u00e7lar\u0131na g\u00f6re, GEN6050X genel olarak iyi tolere edildi. Baz\u0131 hastalarda doz uygulamas\u0131ndan k\u0131sa s\u00fcre sonra ciddi yan etkiler g\u00f6r\u00fcld\u00fc, ancak ara\u015ft\u0131rmac\u0131lar bu yan etkilerin ge\u00e7ici, y\u00f6netilebilir oldu\u011funu ve uzun vadeli sonu\u00e7lar b\u0131rakmadan tamamen ortadan kalkt\u0131\u011f\u0131n\u0131 bildirdi.<\/strong> Uzun s\u00fcreli takip s\u00fcrecinde ara\u015ft\u0131rmac\u0131lar, tedavi g\u00f6ren kat\u0131l\u0131mc\u0131lar aras\u0131nda klinik olarak anlaml\u0131 yeni tedaviyle ili\u015fkili semptom veya laboratuvar anormalli\u011fi tespit etmediler.<\/p>\n\n\n\n<h2 id=\"limitations-of-the-current-clinical-study\" class=\"wp-block-heading\">Mevcut Klinik \u00c7al\u0131\u015fman\u0131n S\u0131n\u0131rlamalar\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bu bulgular umut verici olsa da, bunlar\u0131n dikkatli bir \u015fekilde yorumlanmas\u0131 \u015fartt\u0131r. Mevcut \u00e7al\u0131\u015fma yaln\u0131zca \u00fc\u00e7 hastay\u0131 i\u00e7erdi\u011finden, uzun vadeli etkinlik veya g\u00fcvenlik hakk\u0131nda kesin sonu\u00e7lar \u00e7\u0131karmak m\u00fcmk\u00fcn de\u011fildir. GEN6050X ekzon 50 atlama tedavisinin daha geni\u015f klinik kullan\u0131m i\u00e7in de\u011ferlendirilebilmesi i\u00e7in daha fazla kat\u0131l\u0131mc\u0131 ve daha uzun g\u00f6zlem s\u00fcrelerini i\u00e7eren daha b\u00fcy\u00fck klinik \u00e7al\u0131\u015fmalara ihtiya\u00e7 duyulacakt\u0131r.<\/p>\n\n\n\n<h2 id=\"future-outlook-for-gen-6050-x\" class=\"wp-block-heading\">GEN6050X i\u00e7in Gelecek Beklentileri<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gelecekte yap\u0131lacak \u00e7al\u0131\u015fmalar bu erken sonu\u00e7lar\u0131 do\u011frularsa, GEN6050X ekzon 50 atlama tedavisi, Duchenne kas distrofisi i\u00e7in hassas t\u0131p alan\u0131nda \u00f6nemli bir ilerlemeyi temsil edebilir.<\/strong> Bu yakla\u015f\u0131m, genin bir k\u0131sm\u0131n\u0131 de\u011fi\u015ftirmek yerine, altta yatan genetik mutasyonu do\u011frudan baz d\u00fczenleme yoluyla d\u00fczelterek, ekzon 50 atlamas\u0131na uygun DMD mutasyonlar\u0131n\u0131n tedavisi i\u00e7in yeni olanaklar a\u00e7abilir. <strong>Tedavi hen\u00fcz ara\u015ft\u0131rma a\u015famas\u0131nda olsa da, bir y\u0131ll\u0131k klinik veriler, baz d\u00fczenlemenin Duchenne tedavilerinin geni\u015fleyen yelpazesine \u00f6nemli bir katk\u0131 sa\u011flayabilece\u011fi konusunda temkinli bir iyimserlik sunmaktad\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u015eimdi Ke\u015ffedin<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/clinical-trials\/\" target=\"_blank\" rel=\"noreferrer noopener\">DMDWarrioR Klinik Ara\u015ft\u0131rmalar Merkezi<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The GEN6050X exon 50 skipping base editing drug, developed by GenAssist Therapeutics, is attracting growing attention as one of the first base editing therapies being evaluated for Duchenne muscular dystrophy (DMD). Unlike conventional gene therapies that deliver a shortened version of the dystrophin gene, GEN6050X is designed to precisely edit DNA so that exon 50 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8293,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[123,278,279,475,280,178,277,276],"class_list":["post-8291","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-china","tag-exon-50","tag-exon-50-skipping","tag-exon-50-skipping-therapy","tag-exon-50-skipping-treatment","tag-exon-skipping-therapies","tag-gen6050x","tag-genassist"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8291"}],"version-history":[{"count":2,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8291\/revisions"}],"predecessor-version":[{"id":8294,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8291\/revisions\/8294"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8293"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}